Implications for employers: The White House press release and news reports remain vague about pricing for employer sponsored health plans - so employers should watch closely to see the impact on their acquisition costs
The question behind the question is usually: "How much longer will I be able to get compounded semaglutide at this price?" The pattern we see: patients conflate three separate timelines: Patent expiration (2031-2033 for the formulations that matter) FDA shortage list removal (expected late 2026 to Q1 2027) Generic market entry (2027 for oral, 2031-2032 for injectable, assuming no patent challenges) The timeline that affects current compounded access is number 2, not number 1
Diabetologia 58(5):886899 Wu L, Bai YH, Chen T, Zhang L, Wang YR, Zhu H, Jiao YX, Sun L (2016) The relation of calcium-phosphorus metabolism-related indexes with cardiac damages
Optimizing your semaglutide timeline for the fastest safe results Speed matters, but not at the expense of safety or sustainability
This selectivity has made MT-1 peptide a valuable tool for researchers investigating MC1R-specific signaling pathways
